Pagliusi S.,DCVMN International |
Leite L.C.C.,Instituto Butantan |
Datla M.,Biological E Ltd |
Makhoana M.,The Biovac Institute |
And 5 more authors.
Vaccine | Year: 2013
The Developing Countries Vaccine Manufacturers Network (DCVMN) is a unique model of a public and private international alliance. It assembles governmental and private organizations to work toward a common goal of manufacturing and supplying high-quality vaccines at affordable prices to protect people around the world from known and emerging infectious diseases. Together, this group of manufacturers has decades of experience in manufacturing vaccines, with technologies, know-how, and capacity to produce more than 40 vaccines types. These manufacturers have already contributed more than 30 vaccines in various presentations that have been prequalified by the World Health Organization for use by global immunization programmes. Furthermore, more than 45 vaccines are in the pipeline. Recent areas of focus include vaccines to protect against rotavirus, human papillomavirus (HPV), Japanese encephalitis, meningitis, hepatitis E, poliovirus, influenza, and pertussis, as well as combined pentavalent vaccines for children. The network has a growing number of manufacturers that produce a growing number of products to supply the growing demand for vaccines in developing countries. © 2013 .
Ganu G.,Padmashree Dr D Y Patil Institute Of Pharmaceutical Science And Research |
Garud A.,Padmashree Dr D Y Patil Institute Of Pharmaceutical Science And Research |
Agarwal V.,Padmashree Dr D Y Patil Institute Of Pharmaceutical Science And Research |
Suralkar U.,Padmashree Dr D Y Patil Institute Of Pharmaceutical Science And Research |
And 2 more authors.
Research Journal of Pharmaceutical, Biological and Chemical Sciences | Year: 2011
Mimusops elengi Linn (Sapotaceae) commonly known as Bakul, is a small to large evergreen tree. It is cultivated in gardens as an ornamental tree. Bark is used as a tonic, febrifuge, against odontopathy, inflammation. The part of plants was used in Thai traditional as rejuvenating and neuro tonic remedies, also Mimusops elengi is being screened for acetyl cholinesterase inhibitory activity. Despite the widespread uses of the plant, no scientific work is reported in literature regarding the effect of Mimusops elengi bark against anxiety like states therefore, the present study evaluates the anti-anxiety activity of methanolic, aqueous and n-butanol extract of bark of Mimusops elengi using elevated plus maze in swiss albino mice. Different doses of Test extract was evaluated in animals. Methanol extract at 50,100 and 200 mg/kg, aqueous extract at 100 and 200 while n-butanol extract at 200 mg/kg in mice were active but methanolic extract at 200 mg/kg was found to have more significant anxiolytic activity as compared to aqueous and n-butanol extract. Also activity of methanolic extract at 200 mg/kg was comparable with diazepam.
Ganu G.,Pad Dr Dy Patil Institute |
Jadhav S.,Serum Institute of India |
Deshpande A.,Pad Dr Dy Patil Institute
Acta Chromatographica | Year: 2010
In this paper we describe a simple, precise, and accurate HPTLC method for quantification of lupeol in the bark of Mimosoups elengi (ME). The bark was extracted with hot methanol in a Soxhlet apparatus. Chromatographic separation of the extract was performed on aluminum foil plates coated with silica gel 60 F 254 as the stationary phase. The mobile phase was toluene-ethyl acetate-formic acid 12:2:1 ( υ/υ ). Densitometric evaluation of the separated zones was performed at 220 nm. The lupeol was satisfactorily resolved at R F 0.64 ± 0.02. The accuracy and reliability of the method were assessed by evaluation of linearity (1000-4000 ng per band), precision (method and instrumental precision, as RSD, 1.06 and 1.03%, respectively), accuracy (97.28 ± 0.89), and specificity in accordance with ICH guidelines.
Bash M.C.,Center for Biologics Evaluation and Research |
Lynn F.,Center for Biologics Evaluation and Research |
Mocca B.,Center for Biologics Evaluation and Research |
Borrow R.,Public Health England |
And 8 more authors.
Clinical and Vaccine Immunology | Year: 2014
A meningococcal group A polysaccharide (PS) conjugate vaccine (PsA-TT) has been developed for African countries affected by epidemic meningitis caused by Neisseria meningitidis. Complement-mediated serum bactericidal antibody (SBA) assays are used to assess protective immune responses to meningococcal vaccination. Human complement (hC′) was used in early studies demonstrating antibody-mediated protection against disease, but it is difficult to obtain and standardize. We developed and evaluated a method for sourcing hC′ and then used the SBA assay with hC′ (hSBA) to measure bactericidal responses to PsA-TT vaccination in 12- to 23-month-old African children. Sera with active complement from 100 unvaccinated blood donors were tested for intrinsic bactericidal activity, SBA titer using rabbit complement (rSBA), and anti-group A PS antibody concentration. Performance criteria and pooling strategies were examined and then verified by comparisons of three independently prepared hC′ lots in two laboratories. hSBA titers of clinical trial sera were then determined using this complement sourcing method. Two different functional antibody tests were necessary for screening hC′. hSBA titers determined using three independent lots of pooled hC′ were within expected assay variation among lots and between laboratories. In African toddlers, PsA-TT elicited higher hSBA titers than meningococcal polysaccharide or Hib vaccines. PsA-TT immunization or PS challenge of PsA-TT-primed subjects resulted in vigorous hSBA memory responses, and titers persisted in boosted groups for over a year. Quantifying SBA using pooled hC′ is feasible and showed that PsA-TT was highly immunogenic in African toddlers. Copyright © 2014, American Society for Microbiology. All Rights Reserved.
Ganu G.P.,Dr D Y Patil Institute Of Pharmaceutical Science And Research |
Jadhav S.S.,Serum Institute of India |
Deshpande A.D.,Dr D Y Patil Institute Of Pharmaceutical Science And Research
International Journal of Phytomedicine | Year: 2010
Ayurveda refers Mimusops elengi L. for the treatment of the diabetes. Considering the traditional claim of M. elengi in management of diabetes and the possible involvement of oxidative stress in pathogenesis of diabetes, the present study was aimed to evaluate the in vitro antioxidant and in vivo antihyperglycemic property of methanolic extract of bark of M. elengi (MEMeOH). In vitro antioxidant activity of MEMeOH was evaluated using reducing power assay, DPPH and hydroxyl radical scavenging assay. MEMeOH offered significant in vitro reducing power capacity and radical scavenging activity. In acute study in alloxan induced diabetes, MEMeOH exhibited significant (p< 0.001) antihyperglycemic effect. The onset of antihyperglycemic effect was observed at 2nd hr; peak activity was demonstrated at 6th hr. The antihyperglycemic effect of MEMeOH 400mg/kg, p.o. was persistent up to 24th hr after drug administration. MEMeOH produced significant (p < 0.01) reduction in elevated glucose levels in glucose loaded non diabetic animals. The onset of action in non diabetic oral glucose tolerance test was found to be at 60th min and peak activity was observed at 120th min after oral glucose load. MEMeOH demonstrated significant (p < 0.01) reduction in elevated glucose levels 2hr before glucose administration and 6 hr after glucose load in oral glucose tolerance test in diabetic animals. MEMeOH has demonstrated antihyperglycemic activity in diabetic as well as non diabetic glucose loaded mice. MEMeOH should be further explored against diabetes and related complications. © arjournals.org, All rights reserved.